Sermorelin
GH secretagogue (GHRH 1-29)
Research overview
A growth-hormone-releasing-hormone analog studied in models of pulsatile stimulation of the somatotropic axis.
Descriptions reference published research areas for laboratory context only and are not claims of efficacy, safety, or intended use in humans or animals.
- Price
- $260 CAD
- Purity
- ≥99.1% (HPLC)
- Presentation
- 5 mg lyophilized vial
Order / inquire about Sermorelin
Email our research desk for availability, batch Certificates of Analysis, and account setup. We respond to verified research inquiries from Canada only.
Verified Canadian research inquiries only · 18+
For laboratory research use only — not for human or veterinary use
Sermorelin is a chemical reference material sold strictly for in-vitro laboratory research by qualified professionals. It is not a drug, food, cosmetic, or natural health product; it has not been evaluated or approved by Health Canada; and it must never be ingested, injected, or applied to humans or animals. Sold in Canada only, to purchasers 18+. See our Research Use Policy.
Research encyclopedia
Everything the literature has studied.
For laboratory research use only — not for human or veterinary use. The content below summarizes published research context only. It is not medical advice, makes no therapeutic claims, and describes no intended use in humans or animals. These materials have not been evaluated or approved by Health Canada.
What it is
Synthetic 29-amino-acid peptide identical to the active N-terminal fragment of human growth-hormone-releasing hormone, GHRH(1-29). It is the shortest fragment retaining the full activity of the native 44-aa GHRH, and was historically approved by the FDA (Geref) as a diagnostic agent for growth-hormone deficiency.
Mechanism of action
Binds the GHRH receptor on pituitary somatotrophs, activating adenylate cyclase and raising cAMP, which stimulates synthesis and release of endogenous GH while preserving physiologic pulsatility. Downstream, hepatic IGF-1 rises, supporting protein synthesis and lipid metabolism.
Research areas
- Diagnosis of GH deficiency
- Research in body composition and aging
- Studies of sleep, recovery, and metabolism
Studied effects in research models
- Increase in GH and IGF-1 while preserving physiological pulsatility
- Stimulation of protein synthesis and lipid metabolism
Effects listed describe observations reported in laboratory or animal research models only — not outcomes claimed for humans or animals.
Biomarkers tracked in related research
Discovery & background
Identified in the 1980s as the minimal functional fragment of the 44-residue native GHRH. Developed as a diagnostic and short-acting GH secretagogue; FDA-approved historically (Geref) for GH-deficiency diagnosis. It preserves the natural pulsatile pattern of GH release, distinguishing it from exogenous recombinant GH.
Considerations & limitations
Research use only in this context. Therapeutic efficacy beyond the historical diagnostic indication is limited relative to recombinant GH, and robust long-term data are scarce. As a GH secretagogue, caution applies with active malignancy or oncologic history via the GH/IGF-1 axis; avoid with hypothalamic-pituitary axis disruption; contraindicated in pregnancy/lactation. Monitor glucose given effects on insulin sensitivity. Require COA with HPLC/MS identity and endotoxin testing.
References
- [1]Walker, 2006 (GHRH physiology/sermorelin) — Clin Interv Aging; PMID: 18046908
- [2]Prakash & Goa, 1999 (sermorelin review) — BioDrugs; PMID: 18031142
- [3]Corpas et al., 1993 (GHRH(1-29) in older men) — J Clin Endocrinol Metab; PMID: 8098851